A cancer-stricken liver might be a lonely little organ, thanks to Delcath Systems. The development-stage company's technology allows blood infused with chemotherapy drugs to be pumped directly to the liver and then filtered before being returned into the circulation system. By isolating the liver, Delcath's proprietary Hepatic CHEMOSAT® Delivery System is designed to protect other parts of the body from side effects and allow stronger doses of drugs to be used to treat liver cancer and malignant melanoma that has spread to the liver. The system, undergoing clinical trials to gain FDA approval, is CE Mark-approved in Europe. Delcath is also developing the system for use in treating other cancers and viral hepatitis.